KEGG   DRUG: GevokizumabHelp
Entry
D09911                      Drug                                   

Name
Gevokizumab (USAN/INN)
Formula
C6442H9962N1710O2010S52
Exact mass
145101.5356
Mol weight
145191.6587
Sequence
(Heavy chain)
QVQLQESGPG LVKPSQTLSL TCSFSGFSLS TSGMGVGWIR QPSGKGLEWL AHIWWDGDES
YNPSLKSRLT ISKDTSKNQV SLKITSVTAA DTAVYFCARN RYDPPWFVDW GQGTLVTVSS
ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VTSSNFGTQT YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF
LFPPKPKDTL  MISRTPEVTC  VVVDVSHEDP  EVQFNWYVDG  MEVHNAKTKP  REEQFNSTFR
300 VVSVLTVVHQ  DWLNGKEYKC  KVSNKGLPAP  IEKTISKTKG  QPREPQVYTL
PPSREEMTKN  QVSLTCLVKG  FYPSDIAVEW  ESNGQPENNY  KTTPPMLDSD
GSFFLYSKLT  VDKSRWQQGN  VFSCSVMHEA  LHNHYTQKSL  SLSPG
(Light chain)
DIQMTQSTSS LSASVGDRVT ITCRASQDIS NYLSWYQQKP GKAVKLLIYY TSKLHSGVPS
RFSGSGSGTD YTLTISSLQQ EDFATYFCLQ GKMLPWTFGQ GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H97, H147-H203, H260-H320, H366-H424, H222-H'222, H223-H'223, H226-H'226, 229-H'229, L23-L88, L134-L194, H134-L214)
  Type
Peptide
Class
Other
 DG02019  Interleukin inhibitor
Efficacy
Anti-inflammatory, Immunomodulator, Anti-IL-1beta antibody
Comment
Monoclonal antibody
Treatment of diabetes, inflammatory disorders
Target
IL1B [HSA:3553] [KO:K04519]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04621  NOD-like receptor signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL1B
     D09911  Gevokizumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 1129435-60-4
PubChem: 124490618

» Japanese version   » Back

DBGET integrated database retrieval system